Precision medicine in patients with allergic diseases: Airway diseases and atopic dermatitis - PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology

Journal of Allergy and Clinical Immunology

Volumn 137, Issue 5, 2016, Pages 1347-1358

  Muraro, Antonella ^a   Lemanske, Robert F ^b   Hellings, Peter W ^c   Akdis, Cezmi A ^d   Bieber, Thomas ^e   Casale, Thomas B ^f   Jutel, Marek ^g   Ong, Peck Y ^h   Poulsen, Lars K ⁱ   Schmid Grendelmeier, Peter ^d   Simon, Hans Uwe ^j   Seys, Sven F ^k   Agache, Ioana ^l  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d UNIVERSITY OF ZURICH   (Switzerland)

^e UNIVERSITY OF BONN   (Germany)

^f UNIVERSITY OF SOUTH FLORIDA   (United States)

^g WROCLAW MEDICAL UNIVERSITY   (Poland)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁱ Mental Health Services CPH   (Denmark)

^j UNIVERSITY OF BERN   (Switzerland)

^k UNIVERSITY OF LEUVEN   (Belgium)

^l TRANSILVANIA UNIVERSITY OF BRASOV   (Romania)

more..

Author keywords

allergic asthma; allergic rhinitis; allergic skin disease; biomarker; endotype; Key words Precision medicine; personalized care; phenotype

Indexed keywords

BIOLOGICAL MARKER;

ALLERGIC DISEASE; ASTHMA; ATOPIC DERMATITIS; HUMAN; IMMUNE RESPONSE; PATHOGENESIS; PERSONALIZED MEDICINE; PHENOTYPE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; RHINITIS; CONSENSUS DEVELOPMENT; DERMATITIS, ATOPIC; EUROPE; HEALTH CARE ORGANIZATION; IMMUNOLOGY; RESPIRATORY SYSTEM; SKIN;

ASTHMA; DERMATITIS, ATOPIC; EUROPE; HUMANS; PRECISION MEDICINE; RESPIRATORY SYSTEM; RHINITIS; SKIN; SOCIETIES, SCIENTIFIC;

EID: 84964805747     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2016.03.010     Document Type: Review

References (97)

1. F.S. Collins, and H. Varmus A new initiative on precision medicine N Engl J Med 372 2015 793 795
2. C.A. Akdis, M. Akdis, T. Bieber, C. Bindslev-Jensen, M. Boguniewicz, P. Eigenmann, and et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report Allergy 61 2006 969 987
3. I. Agache, C. Akdis, M. Jutel, and J.C. Virchow Untangling asthma phenotypes and endotypes Allergy 67 2012 835 846
4. S.E. Wenzel Asthma phenotypes: the evolution from clinical to molecular approaches Nat Med 18 2012 716 725
5. J.V. Fahy Type 2 inflammation in asthma - present in most, absent in many Nat Rev Immunol 15 2015 57 65
6. B.N. Lambrecht, and H. Hammad The immunology of asthma Nat Immunol 16 2015 45 56
7. I.O. Agache From phenotypes to endotypes to asthma treatment Curr Opin Allergy Clin Immunol 13 2013 249 256
8. M.L. Fajt, and S.E. Wenzel Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care J Allergy Clin Immunol 135 2015 299 311
9. P.G. Woodruff, B. Modrek, D.F. Choy, G. Jia, A.R. Abbas, A. Ellwanger, and et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma Am J Respir Crit Care Med 180 2009 388 395
10. C.E. Brightling, F.A. Symon, S.S. Birring, P. Bradding, I.D. Pavord, and A.J. Wardlaw TH2 cytokine expression in bronchoalveolar lavage fluid T lymphocytes and bronchial submucosa is a feature of asthma and eosinophilic bronchitis J Allergy Clin Immunol 110 2002 899 905
11. S.-H. Cho, L.A. Stanciu, S.T. Holgate, and S.L. Johnston Increased interleukin-4, interleukin-5, and interferon-gamma in airway CD4+ and CD8+ T cells in atopic asthma Am J Respir Crit Care Med 171 2005 224 230
12. M.A. Berry, D. Parker, N. Neale, L. Woodman, A. Morgan, P. Monk, and et al. Sputum and bronchial submucosal IL-13 expression in asthma and eosinophilic bronchitis J Allergy Clin Immunol 114 2004 1106 1109
13. E. Truyen, L. Coteur, E. Dilissen, L. Overbergh, L.J. Dupont, J.L. Ceuppens, and et al. Evaluation of airway inflammation by quantitative Th1/Th2 cytokine mRNA measurement in sputum of asthma patients Thorax 61 2006 202 208
14. S.K. Saha, M.A. Berry, D. Parker, S. Siddiqui, A. Morgan, R. May, and et al. Increased sputum and bronchial biopsy IL-13 expression in severe asthma J Allergy Clin Immunol 121 2008 685 691
15. M.C. Peters, Z.K. Mekonnen, S. Yuan, N.R. Bhakta, P.G. Woodruff, and J.V. Fahy Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma J Allergy Clin Immunol 133 2014 388 394
16. R.H. Green, C.E. Brightling, G. Woltmann, D. Parker, A.J. Wardlaw, and I.D. Pavord Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids Thorax 57 2002 875 879
17. P. Haldar, C.E. Brightling, B. Hargadon, S. Gupta, W. Monteiro, A. Sousa, and et al. Mepolizumab and exacerbations of refractory eosinophilic asthma N Engl J Med 360 2009 973 984
18. P. Nair, M.M. Pizzichini, M. Kjarsgaard, M.D. Inman, A. Efthimiadis, E. Pizzichini, and et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia N Engl J Med 360 2009 985 993
19. I. Agache, K. Sugita, H. Morita, M. Akdis, and C. Akdis The complex type 2 endotype in allergy and asthma: from laboratory to bedside Curr Allergy Asthma Rep 15 2015 29
20. J.P. Rajan, N.E. Wineinger, D.D. Stevenson, and A.A. White Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature J Allergy Clin Immunol 135 2015 676 681.e1
21. J.W. Steinke, L. Liu, P. Huyett, J. Negri, S.C. Payne, and L. Borish Prominent role of IFN-γ in patients with aspirin-exacerbated respiratory disease J Allergy Clin Immunol 134 2013 856 865 e1-3
22. S.F. Seys, M. Grabowski, W. Adriaensen, A. Decraene, E. Dilissen, J.A. Vanoirbeek, and et al. Sputum cytokine mapping reveals an "IL-5, IL-17A, IL-25-high" pattern associated with poorly controlled asthma Clin Exp allergy 43 2013 1009 1017
23. G.S. Marijsse, S.F. Seys, A.-S. Schelpe, E. Dilissen, P. Goeminne, L.J. Dupont, and et al. Obese individuals with asthma preferentially have a high IL-5/IL-17A/IL-25 sputum inflammatory pattern Am J Respir Crit Care Med 189 2014 1284 1285
24. A. Lindén, and B. Dahlén Interleukin-17 cytokine signalling in patients with asthma Eur Respir J 44 2014 1319 1331
25. E.S. Chambers, A.M. Nanzer, P.E. Pfeffer, D.F. Richards, P.M. Timms, A.R. Martineau, and et al. Distinct endotypes of steroid-resistant asthma characterized by IL-17A(high) and IFN-γ(high) immunophenotypes: potential benefits of calcitriol J Allergy Clin Immunol 136 2015 628 637.e4
26. S. Conus, A. Bruno, and H.-U. Simon Leptin is an eosinophil survival factor J Allergy Clin Immunol 116 2005 1228 1234
27. F. Holguin, S.A.A. Comhair, S.L. Hazen, R.W. Powers, S.S. Khatri, E.R. Bleecker, and et al. An association between L-arginine/asymmetric dimethyl arginine balance, obesity, and the age of asthma onset phenotype Am J Respir Crit Care Med 187 2013 153 159
28. D.C. Cowan, D.R. Taylor, L.E. Peterson, J.O. Cowan, R. Palmay, A. Williamson, and et al. Biomarker-based asthma phenotypes of corticosteroid response J Allergy Clin Immunol 135 2015 877 883.e1
29. Y. Xie, H. Jiang, H. Nguyen, S. Jia, A. Berro, R.A. Panettieri, and et al. Regulator of G protein signaling 2 is a key modulator of airway hyperresponsiveness J Allergy Clin Immunol 130 2012 968 976.e3
30. S.T. Holgate Epithelium dysfunction in asthma J Allergy Clin Immunol 120 2007 1233 1246
31. C. Xiao, S.M. Puddicombe, S. Field, J. Haywood, V. Broughton-Head, I. Puxeddu, and et al. Defective epithelial barrier function in asthma J Allergy Clin Immunol 128 2011 549 556 e1-12
32. R.H. Dougherty, S.S. Sidhu, K. Raman, M. Solon, O.D. Solberg, G.H. Caughey, and et al. Accumulation of intraepithelial mast cells with a unique protease phenotype in T(H)2-high asthma J Allergy Clin Immunol 125 2010 1046 1053.e8
33. N.-R. Han, H.-A. Oh, S.-Y. Nam, P.-D. Moon, D.-W. Kim, H.-M. Kim, and et al. TSLP induces mast cell development and aggravates allergic reactions through the activation of MDM2 and STAT6 J Invest Dermatol 134 2014 2521 2530
34. M.B. Soyka, P. Wawrzyniak, T. Eiwegger, D. Holzmann, A. Treis, K. Wanke, and et al. Defective epithelial barrier in chronic rhinosinusitis: the regulation of tight junctions by IFN-γ and IL-4 J Allergy Clin Immunol 130 2012 1087 1096.e10
35. D.M. Bullens, E. Truyen, L. Coteur, E. Dilissen, P.W. Hellings, L.J. Dupont, and et al. IL-17 mRNA in sputum of asthmatic patients: linking T cell driven inflammation and granulocytic influx? Respir Res 7 2006 135
36. J. Pene, S. Chevalier, L. Preisser, E. Venereau, M.-H. Guilleux, S. Ghannam, and et al. Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes J Immunol 180 2008 7423 7430
37. J.L. Simpson, P.G. Gibson, I.A. Yang, J. Upham, A. James, P.N. Reynolds, and et al. Impaired macrophage phagocytosis in non-eosinophilic asthma Clin Exp Allergy 43 2013 29 35
38. K.J. Baines, J.L. Simpson, L.G. Wood, R.J. Scott, N.L. Fibbens, H. Powell, and et al. Sputum gene expression signature of 6 biomarkers discriminates asthma inflammatory phenotypes J Allergy Clin Immunol 133 2014 997 1007
39. D. Raedler, N. Ballenberger, E. Klucker, A. Böck, R. Otto, O. Prazeres da Costa, and et al. Identification of novel immune phenotypes for allergic and nonallergic childhood asthma J Allergy Clin Immunol 135 2015 81 91
40. M. Raundhal, C. Morse, A. Khare, T.B. Oriss, J. Milosevic, J. Trudeau, and et al. High IFN-γ and low SLPI mark severe asthma in mice and humans J Clin Invest 125 2015 3037 3050
41. Guidance for industry - pharmacogenomic data submissions. 2005. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126957.pdf. Accessed March 30, 2016.
42. J.A. Wagner Overview of biomarkers and surrogate endpoints in drug development Dis Markers 18 2002 41 46
43. J.A. Wagner, S.A. Williams, and C.J. Webster Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs Clin Pharmacol Ther 81 2007 104 107
44. F.M. Goodsaid, F.W. Frueh, and W. Mattes Strategic paths for biomarker qualification Toxicology 245 2008 219 223
45. S.E. Wenzel, L. Wang, and G. Pirozzi Dupilumab in persistent asthma N Engl J Med 369 2013 1276
46. I.D. Pavord, S. Korn, P. Howarth, E.R. Bleecker, R. Buhl, O.N. Keene, and et al. Mepolizumab for severe eosinophilic asthma (DREAM): A multicentre, double-blind, placebo-controlled trial Lancet 380 2012 651 659
47. H.G. Ortega, M.C. Liu, I.D. Pavord, G.G. Brusselle, J.M. FitzGerald, A. Chetta, and et al. Mepolizumab treatment in patients with severe eosinophilic asthma N Engl J Med 371 2014 1198 1207
48. E.H. Bel, S.E. Wenzel, P.J. Thompson, C.M. Prazma, O.N. Keene, S.W. Yancey, and et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma N Engl J Med 371 2014 1189 1197
49. P.G. Woodruff, H.A. Boushey, G.M. Dolganov, C.S. Barker, Y.H. Yang, S. Donnelly, and et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids Proc Natl Acad Sci U S A 104 2007 15858 15863
50. G. Jia, R.W. Erickson, D.F. Choy, S. Mosesova, L.C. Wu, O.D. Solberg, and et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients J Allergy Clin Immunol 130 2012 647 654.e10
51. J. Corren, R.F. Lemanske, N.A. Hanania, P.E. Korenblat, M.V. Parsey, J.R. Arron, and et al. Lebrikizumab treatment in adults with asthma N Engl J Med 365 2011 1088 1098
52. C.E. Brightling, P. Chanez, R. Leigh, P.M. O'Byrne, S. Korn, D. She, and et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: A randomised, double-blind, placebo-controlled, phase 2b trial Lancet Respir Med 3 2015 692 701
53. E. Piper, C. Brightling, R. Niven, C. Oh, R. Faggioni, K. Poon, and et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma Eur Respir J 41 2013 330 338
54. N.A. Hanania, S. Wenzel, K. Rosén, H.-J. Hsieh, S. Mosesova, D.F. Choy, and et al. Exploring the effects of omalizumab in allergic asthma: An analysis of biomarkers in the EXTRA study Am J Respir Crit Care Med 187 2013 804 811
55. W. Busse, S. Spector, K. Rosén, Y. Wang, and O. Alpan High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects J Allergy Clin Immunol 132 2013 485 486.e11
56. M.P. van der Schee, R. Palmay, J.O. Cowan, and D.R. Taylor Predicting steroid responsiveness in patients with asthma using exhaled breath profiling Clin Exp Allergy 43 2013 1217 1225
57. N. Fens, K.F. van der Sluijs, M.A. van de Pol, A. Dijkhuis, B.S. Smids, J.S. van der Zee, and et al. Electronic nose identifies bronchoalveolar lavage fluid eosinophils in asthma Am J Respir Crit Care Med 191 2015 1086 1088
58. L.-B. Li, D.Y.M. Leung, and E. Goleva Activated p38 MAPK in peripheral blood monocytes of steroid resistant asthmatics PLoS One 10 2015 e0141909
59. C. Xiao, J.M. Biagini Myers, H. Ji, K. Metz, L.J. Martin, M. Lindsey, and et al. Vanin-1 expression and methylation discriminate pediatric asthma corticosteroid treatment response J Allergy Clin Immunol 136 2015 923 931.e3
60. C. Irvin, I. Zafar, J. Good, D. Rollins, C. Christianson, M.M. Gorska, and et al. Increased frequency of dual-positive TH2/TH17 cells in bronchoalveolar lavage fluid characterizes a population of patients with severe asthma J Allergy Clin Immunol 134 2014 1175 1186.e7
61. B.J. Lipworth Biomarkers to predict inhaled corticosteroid response J Allergy Clin Immunol 136 2015 515
62. E. Goleva, L.P. Jackson, J.K. Harris, C.E. Robertson, E.R. Sutherland, C.F. Hall, and et al. The effects of airway microbiome on corticosteroid responsiveness in asthma Am J Respir Crit Care Med 188 2013 1193 1201
63. G.L. Clemmer, A.C. Wu, B. Rosner, M.J. McGeachie, A.A. Litonjua, K.G. Tantisira, and et al. Measuring the corticosteroid responsiveness endophenotype in asthmatic patients J Allergy Clin Immunol 136 2015 274 281.e8
64. M.J. Leckie, A. ten Brinke, J. Khan, Z. Diamant, B.J. O'Connor, C.M. Walls, and et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response Lancet 356 2000 2144 2148
65. P. Flood-Page, C. Swenson, I. Faiferman, J. Matthews, M. Williams, L. Brannick, and et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma Am J Respir Crit Care Med 176 2007 1062 1071
66. O. Boyman, C. Kaegi, M. Akdis, S. Bavbek, A. Bossios, A. Chatzipetrou, and et al. EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders Allergy 70 2015 727 754
67. S. Radonjic-Hoesli, P. Valent, A.D. Klion, M.E. Wechsler, and H.-U. Simon Novel targeted therapies for eosinophil-associated diseases and allergy Annu Rev Pharmacol Toxicol 55 2015 633 656
68. R. Pettipher, M.G. Hunter, C.M. Perkins, L.P. Collins, T. Lewis, M. Baillet, and et al. Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459 Allergy 69 2014 1223 1232
69. P. Haldar, C.E. Brightling, A. Singapuri, B. Hargadon, S. Gupta, W. Monteiro, and et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis J Allergy Clin Immunol 133 2014 921 923
70. J. Bousquet, N. Khaltaev, A.A. Cruz, J. Denburg, W.J. Fokkens, A. Togias, and et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen) Allergy 63 suppl 8 2008 8 160
71. J.L. Brozek, J. Bousquet, C.E. Baena-Cagnani, S. Bonini, G.W. Canonica, T.B. Casale, and et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision J Allergy Clin Immunol 126 2010 466 476
72. P.W. Hellings, W.J. Fokkens, C. Akdis, C. Bachert, C. Cingi, D. Dietz de Loos, and et al. Uncontrolled allergic rhinitis and chronic rhinosinusitis: where do we stand today? Allergy 68 2013 1 7
73. N.G. Papadopoulos, J.A. Bernstein, P. Demoly, M. Dykewicz, W. Fokkens, P.W. Hellings, and et al. Phenotypes and endotypes of rhinitis and their impact on management: A PRACTALL report Allergy 70 2015 474 494
74. C.A. Akdis, C. Bachert, C. Cingi, M.S. Dykewicz, P.W. Hellings, R.M. Naclerio, and et al. Endotypes and phenotypes of chronic rhinosinusitis: A PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology J Allergy Clin Immunol 131 2013 1479 1490
75. A.M. Bentley, M.R. Jacobson, V. Cumberworth, J.R. Barkans, R. Moqbel, L.B. Schwartz, and et al. Immunohistology of the nasal mucosa in seasonal allergic rhinitis: increases in activated eosinophils and epithelial mast cells J Allergy Clin Immunol 89 1992 877 883
76. A.N. Greiner, P.W. Hellings, G. Rotiroti, and G.K. Scadding Allergic rhinitis Lancet 378 2011 2112 2122
77. R. Castano, K. Maghni, L. Castellanos, C. Trudeau, J.-L. Malo, and D. Gautrin Proinflammatory mediators in nasal lavage of subjects with occupational rhinitis Otolaryngol Neck Surg 143 2010 301 303.e1
78. V. Hox, B. Steelant, W. Fokkens, B. Nemery, and P.W. Hellings Occupational upper airway disease: how work affects the nose Allergy 69 2014 282 291
79. M. Wang, W. Zhang, J. Shang, J. Yang, L. Zhang, and C. Bachert Immunomodulatory effects of IL-23 and IL-17 in a mouse model of allergic rhinitis Clin Exp Allergy 43 2013 956 966
80. L. Van Gerven, Y.A. Alpizar, M.M. Wouters, V. Hox, E. Hauben, M. Jorissen, and et al. Capsaicin treatment reduces nasal hyperreactivity and transient receptor potential cation channel subfamily V, receptor 1 (TRPV1) overexpression in patients with idiopathic rhinitis J Allergy Clin Immunol 133 2014 1332 1339 e1-3
81. B. Steelant, R. Farré, P. Wawrzyniak, J. Belmans, E. Dekimpe, H. Vanheel, and et al. Impaired barrier function in patients with house dust mite-induced allergic rhinitis is accompanied by decreased occludin and zonula occludens-1 expression J Allergy Clin Immunol 137 2016 1043 1053.e5
82. M. Jutel, I. Agache, S. Bonini, A.W. Burks, M. Calderon, W. Canonica, and et al. International Consensus on Allergen Immunotherapy II: mechanisms, standardization, and pharmacoeconomics J Allergy Clin Immunol 137 2016 358 368
83. M. Jutel, I. Agache, S. Bonini, A.W. Burks, M. Calderon, W. Canonica, and et al. International consensus on allergy immunotherapy J Allergy Clin Immunol 136 2015 556 568
84. S. Noda, M. Suárez-Fariñas, B. Ungar, S.J. Kim, C. de Guzman Strong, H. Xu, and et al. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization J Allergy Clin Immunol 136 2015 1254 1264
85. S. Weidinger, and N. Novak Atopic dermatitis Lancet 387 2016 1109 1122
86. T. Czarnowicki, H. Esaki, J. Gonzalez, D. Malajian, A. Shemer, S. Noda, and et al. Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)(+) TH2/TH1 cell imbalance, whereas adults acquire CLA(+) TH22/TC22 cell subsets J Allergy Clin Immunol 136 2015 941 951.e3
87. T. Bieber Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and stratified medicine Allergy 67 2012 1475 1482
88. T. Czarnowicki, J. Gonzalez, A. Shemer, D. Malajian, H. Xu, X. Zheng, and et al. Severe atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22, but not TH17/TC17, cells within the skin-homing T-cell population J Allergy Clin Immunol 136 2015 104 115.e7
89. H. Hammad, and B.N. Lambrecht Barrier epithelial cells and the control of type 2 immunity Immunity 43 2015 29 40
90. T. Bieber, M. Cork, and S. Reitamo Atopic dermatitis: A candidate for disease-modifying strategy Allergy 67 2012 969 975
91. T. Bieber, and F. Nestle Personalized treatment options in dermatology 2015 Springer Berlin
92. L.A. Beck, D. Thaçi, J.D. Hamilton, N.M. Graham, T. Bieber, R. Rocklin, and et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis N Engl J Med 371 2014 130 139
93. O. Nemoto, M. Furue, H. Nakagawa, M. Shiramoto, R. Hanada, S. Matsuki, and et al. The first trial of CIM331, a humanized anti-human IL-31 receptor A antibody, for healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomised, double-blind, placebo-controlled Br J Dermatol 174 2016 296 304
94. T. Bieber Stratified medicine: A new challenge for academia, industry, regulators and patients 2013 Future Medicine London 75
95. A. Staudacher, T. Hinz, N. Novak, D. von Bubnoff, and T. Bieber Exaggerated IDO1 expression and activity in Langerhans cells from patients with atopic dermatitis upon viral stimulation: A potential predictive biomarker for high risk of eczema herpeticum Allergy 70 2015 1432 1439
96. E.L. Simpson, J.R. Chalmers, J.M. Hanifin, K.S. Thomas, M.J. Cork, W.H.I. McLean, and et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention J Allergy Clin Immunol 134 2014 818 823
97. K. Horimukai, K. Morita, M. Narita, M. Kondo, H. Kitazawa, M. Nozaki, and et al. Application of moisturizer to neonates prevents development of atopic dermatitis J Allergy Clin Immunol 134 2014 824 830.e6